CLEARWATER, Fla. / Nov 07, 2023 / Business Wire / Apyx Medical Corporation (NASDAQ:APYX) (the “Company”), the manufacturer of a proprietary helium plasma and radiofrequency technology marketed and sold as Renuvion®, announced today that management will participate in the following upcoming investor conferences:
The Stephens Annual Investment Conference at the Nashville Grand Hyatt in Nashville, TN
The Craig-Hallum 14th Annual Alpha Select Conference at the Sheraton NY Times Square Hotel in New York, NY
The Piper Sandler 35th Annual Healthcare Conference at the Lotte New York Palace in New York, NY
Audio webcasts of the fireside chat will be provided under the ‘Company Events’ section of the Apyx Medical Corporation investor relations website at https://apyxmedical.com/investor_relations/. The webcasts will be achieved and available for replay following the conferences.
About Apyx Medical Corporation
Apyx Medical Corporation is an advanced energy technology company with a passion for elevating people’s lives through innovative products, including its Helium Plasma Technology products marketed and sold as Renuvion in the cosmetic surgery market and J-Plasma® in the hospital surgical market. Renuvion and J-Plasma offer surgeons a unique ability to provide controlled heat to tissue to achieve their desired results. The Company also leverages its deep expertise and decades of experience in unique waveforms through OEM agreements with other medical device manufacturers. For further information about the Company and its products, please refer to the Apyx Medical Corporation website at www.ApyxMedical.com.
| Last Trade: | US$3.03 |
| Daily Change: | 0.08 2.71 |
| Daily Volume: | 29,185 |
| Market Cap: | US$114.590M |
October 13, 2025 September 29, 2025 August 07, 2025 July 28, 2025 | |

Compass Therapeutics is a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. The company's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth...
CLICK TO LEARN MORE
Chimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....
CLICK TO LEARN MOREEnd of content
No more pages to load